Can Pfizer Seize Share in This Multibillion-Dollar Market?
Earlier this month, Pfizer (NYSE: PFE) announced promising top-line phase 2b/3 results in a study testing its JAK inhibitor ritlecitinib for treatment of alopecia areata, which suggests the drug could eventually be approved for the treatment of this autoimmune disease that causes hair loss.
But as fellow Fool Jeff Little noted in June, "The FDA has recently placed increased focus on the potential side effects of JAK inhibitors ..., which belong to a family of treatments called DMARDs (disease-modifying antirheumatic drugs)." Let's take a look at the results of the study, what the FDA's concerns mean for this drug and others like it, and whether pharmaceutical giant Pfizer has a chance at making its mark in the growing global alopecia drug market.
Image Source: Getty Images.
Source Fool.com
